Abstract
Abstract PURPOSE: Cancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the US. Early clinical diagnosis of bladder cancer remains a major challenge and the development of noninvasive methods for detection and surveillance is desirable for both patients and health care providers. METHODS: In order to identify urinary proteins with potential clinical utility we enriched and profiled the glycoprotein component of urine samples using a dual-lectin affinity chromatography and LC-MS/MS platform. RESULTS: From a primary sample set obtained from 56 cancer patients and 47 healthy individuals, a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker disease association was performed on second set of 70 independent samples using an antibody-lectin sandwich microarray and ELISA. Increased levels of urinary alpha-1-antitrypsin (A1AT) glycoprotein were identified and confirmed as being indicative of the presence of bladder cancer (p value < 0.0001). CONCLUSION: The described strategy can be used to discover biomarkers for disease status in other body fluids. Application of the strategy in this study has provided novel candidate biomarkers for the non-invasive molecular detection of bladder cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4160. doi:10.1158/1538-7445.AM2011-4160
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
